Wednesday was a bad day for investors of Spectrum Pharmaceuticals as it toppled more than 35% due to a significant reduction of estimated sales of its flagship product, Fusilev. Generic leucovorin, which had been absent from the market started to return and materially affected orders for Spectrum's branded drug.
In this video, Motley Fool analyst David Williamson recaps the recent news and picks up the pieces for investors taking a look at the drugs in Spectrum's pipeline, including cancer drug Apaziquone, which it recently regained the rights to from Allergan.
Is Spectrum a buy at these new lower prices, or should investors proceed with caution? Watch and find out.
Before investing in a stock like Spectrum, I urge you to read this brand-new Motley Fool special free report, "What's Really Eating at America's Competitiveness." Find out what has Warren Buffett concerned for the future of the U.S. and discover a little-known stock poised to profit from a major government initiative to combat this looming crisis. Grab your free copy today by clicking here.